AstraZeneca account map & org chart

Nine executives sit on the Senior Executive Team with CEO Pascal Soriot¹. R&D is split in two: Susan Galbraith runs Oncology R&D and Sharon Barr runs BioPharmaceuticals R&D. Commercial is split the same way: David Fredrickson runs the Oncology Business Unit and Ruud Dobber the BioPharmaceuticals Business Unit, with Iskra Reic running the International region (China, Asia, the Middle East and Africa, Latin America, Australia and New Zealand). Marc Dunoyer is CEO of Alexion, the rare-disease business, and Chief Strategy Officer. Pam Cheng runs Global Operations, IT and sustainability; Aradhana Sarin is CFO; Jeff Pott is Chief Human Resources Officer, Chief Compliance Officer and General Counsel.

• We found 394 AstraZeneca teams hiring in the past four quarters, and 10,882 leaders at Associate Director level or above. All of it from public sources.
• Oncology hires the most by far: 393 open roles in the past four quarters, then Cardiovascular, Renal & Metabolism (291), Cell Therapy (123, 4.7 times its prior window) and Respiratory & Immunology (109). Respiratory Specialty Care is growing fastest, from 5 roles to 29. Observed postings across the company held roughly flat at 0.9 times the prior window.
• Hiring is more international than at U.S. peers: the United States leads with 1,223 location listings, but China follows with 559, then Spain (158), Poland (148) and Vietnam (142). The busiest cities are Gaithersburg (252), Warsaw (232), Shanghai (184), Barcelona (183) and Wilmington (182).
• AstraZeneca reports its business as one reportable segment, Pharmaceuticals².

The 30 most active units by open roles in the trailing four quarters, of 394 units with any hiring activity in the window (drawn from 5,216 verbatim-extracted unit-name candidates). Rows are centers of activity, not an org chart — several (therapeutic areas especially) sit inside larger divisions rather than beside them. = corroborated by 2+ independent sources.

Reading the momentum column

Momentum is the unit's own posting count, last four quarters vs the four before: ▲ 2.0× = twice as many postings. The arrow marks units moving well beyond (or against) the company-wide trend (0.9× for AstraZeneca), so growth that merely tracks the company shows its multiple without an arrow. Too little history shows "—" rather than a noisy number.

How to use this page. A unit gaining hiring share is standing up capacity — the best moment to engage is while teams and tooling are still being chosen. A unit losing share may be post-reorg, outsourcing, or completing a build-out; treat the flag as a prompt to ask, not a conclusion.

Posting locations for the trailing four quarters of hiring, aggregated across all mapped units. Counts are location listings — a posting advertised in several locations counts once per location, so totals exceed distinct postings. Use this to route territory and plan on-site coverage.

Named Associate Director+ leadership for the busiest centers of work. Every row is flagged for currency: verified = confirmed as current during this snapshot's verification pass (a web check, an active-position signal, or the company's own page); verify = sourced but not recently re-confirmed — check before outreach. In this public edition, a lock marks a leader named in the full map.

Centers whose own staff lead-author peer-reviewed papers, from author affiliations in the scientific literature (2023–2026). Papers attach to a center only when the paper's affiliation names it exactly, so counts are lead-authored published evidence, not a census; 112 mapped centers carry publications in total — the most in this series. Several of these centers barely hire publicly — the literature is the only channel that surfaces them.

The full map lists each center's papers, the diseases, targets, techniques, and instruments they name, and which leaders close the author list on the center's own work — independent corroboration that they run the group.

AstraZeneca's stated leadership structure, drawn as reported: the Senior Executive Team as the company lists it¹, with each executive's organization taken from the leadership page, the annual report on Form 20-F, or the careers site. Every numbered superscript links to its source. A blue count on a card marks an organization whose internal structure is mapped in the following sections: official sub-organizations as boxes, observed teams as ◦ chips. AstraZeneca reports one reportable segment², so there are no segment badges to draw.

Reading order for the next two sections: the two R&D organizations first, then the two business units, International, Alexion, and the enabling functions. The source document drew the Alexion CEO as the chart root; that is corrected here — Pascal Soriot is Chief Executive Officer.

Boxes are official organizations as AstraZeneca describes them on its careers site⁴·⁵ — recruiting copy rather than a governance source, so treat the boxes as the company's own description of how each R&D organization is arranged, not a reporting chart. Muted chips marked ◦ are teams observed in AstraZeneca's hiring activity and scientific literature, attached beneath the official unit they sit in.

The two commercial business units, the International region, Alexion, and the enabling functions, mapped the same way — official cited boxes, observed ◦ chips.

International and the enabling functions

The International region as the 2025 annual report describes it⁹, and the enabling functions as the careers site groups them — recruiting copy, not a governance source.

How is AstraZeneca organized in 2026?

Nine executives sit on the Senior Executive Team with CEO Pascal Soriot¹. R&D is split into Oncology R&D (Susan Galbraith) and BioPharmaceuticals R&D (Sharon Barr). Commercial is split into the Oncology Business Unit (David Fredrickson) and the BioPharmaceuticals Business Unit (Ruud Dobber), with Iskra Reic running the International region. Marc Dunoyer is CEO of Alexion, the rare-disease business, and Chief Strategy Officer. Pam Cheng runs Global Operations, IT and sustainability, Aradhana Sarin is CFO, and Jeff Pott is Chief Human Resources Officer, Chief Compliance Officer and General Counsel. AstraZeneca reports one segment: Pharmaceuticals.

Who leads AstraZeneca's research and development?

Two executives. Susan Galbraith, Executive Vice-President, Oncology R&D, has global responsibility for oncology and haematology R&D from discovery through late-stage development. Sharon Barr, Executive Vice-President, BioPharmaceuticals R&D, covers cardiovascular, renal and metabolism, respiratory and immunology, and vaccines and immune therapies. Rare-disease R&D sits inside Alexion under Marc Dunoyer.

Which AstraZeneca units are hiring the fastest in 2026?

Compared with the four quarters before, Respiratory Specialty Care grew 5.8 times (5 roles to 29), Cell Therapy 4.7 times (26 to 123), Medical Affairs 2.5 times (4 to 10), Hypertension and the Advanced Specialty Team 2.3 times, and Biologics 2.1 times (20 to 42). Observed postings across the company ran at 0.9 times the prior window, so all of these are growing faster than AstraZeneca as a whole. By volume, Oncology posts the most roles (393), then Cardiovascular, Renal & Metabolism (291) and Cell Therapy (123).

Where is AstraZeneca hiring?

The United States leads with 1,223 location listings, but China is close behind with 559, then Spain (158), Poland (148), Vietnam (142), the United Kingdom (122) and Germany (121). The busiest cities are Gaithersburg (252), Warsaw (232), Shanghai (184), Barcelona (183) and Wilmington (182).

What is an account map?

A view of a large company one level below the org chart: the named teams and departments where budgets get spent and vendors get chosen. We rank them by hiring activity and show who leads them, using only what the company makes public. That means job postings, scientific papers, leadership pages, and regulatory filings. This page is the redacted version; the full PDF names every leader we identified.